Defeating MYC with drug combinations or dual-targeting drugs
- Author(s)
- Thompson, PE; Shortt, J;
- Details
- Publication Year 2024-06,Volume 45,Issue #6,Page 490-502
- Journal Title
- Trends in Pharmacological Sciences
- Publication Type
- Review
- Abstract
- Members of the MYC family of proteins are a major target for cancer drug discovery, but the development of drugs that block MYC-driven cancers has not yet been successful. Approaches to achieve success may include the development of combination therapies or dual-acting drugs that target MYC at multiple nodes. Such treatments hold the possibility of additive or synergistic activity, potentially reducing side effect profiles and the emergence of resistance. In this review, we examine the prominent MYC-related targets and highlight those that have been targeted in combination and/or dual-target approaches. Finally, we explore the challenges of combination and dual-target approaches from a drug development perspective.
- Publisher
- Cell Press
- Keywords
- Humans; *Neoplasms/drug therapy; *Proto-Oncogene Proteins c-myc/genetics/metabolism/antagonists & inhibitors; *Antineoplastic Agents/pharmacology; Animals; Molecular Targeted Therapy; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Myc; anti-cancer drug discovery; combination therapies; dual target drugs
- Department(s)
- Clinical Haematology
- Publisher's Version
- https://doi.org/10.1016/j.tips.2024.04.008
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-27 07:14:39
Last Modified: 2024-08-27 07:28:18